Coronary artery disease in outpatients with nonvalvular atrial fibrillation: results from the multicenter RAMSES study
![](/xmlui/themes/Mirage2//images/mime.png)
Tarih
2016Yazar
Dogan, VolkanBasaran, Ozcan
Beton, Osman
Tekinalp, Mehmet
Bolat, Ismail
Kalaycioglu, Ezgi
Aykan, Ahmet Cagri
Tasar, Onur
Safak, Ozgen
Kalcik, Macit
Yaman, Mehmet
Kirma, Cevat
Biteker, Murat
Üst veri
Tüm öğe kaydını gösterÖzet
Background Nonvalvular atrial fibrillation (NVAF) frequently coexists with coronary artery disease (CAD). However, the optimal antithrombotic strategy for patients with concomitant CAD and NVAF is controversial. The aim of this study is to assess the prevalence of CAD with NVAF and to determine antithrombotic treatment options in patients with or without a history of CAD. Methods ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in Turkey (RAMSES study) was a cross-sectional, multicenter, nationwide observational study carried out in NVAF patients. We studied the clinical data of 6264 Turkish patients participating in the RAMSES study. Demographic properties and antithrombotic therapies were recorded and compared between patients with and without CAD. Results CAD was present in 1828 (29.2%) of patients with NVAF. Most of the NVAF patients with CAD were men (58%) and comorbid diseases were significantly more common in patients with CAD. Although patients with CAD had higher CHA(2)DS(2)VASc scores than those without disease (4.1 +/- 1.5 vs. 2.9 +/- 1.5; P=0.001), they had lower use of oral anticoagulant (OAC) therapy (66.1 vs. 74.4%, P=0.01). Among OAC drugs, warfarin was the preferred medication in patients with CAD (35.4 vs. 30.6%, P=0.01), whereas nonvitamin K antagonist oral anticoagulants were preferred in patients without CAD (40 vs. 34.3%, P=0.01). Patients with CAD required nearly three-fold higher antiplatelet treatment compared with patients without CAD (57.8 vs. 21.4%, P<0.001). Conclusion CAD affects nearly one-third of patients with NVAF in a real-world setting. Although they merit more aggressive therapy, patients with CAD and NVAF were less likely to receive OAC therapy. Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.
Kaynak
CORONARY ARTERY DISEASECilt
27Sayı
6Koleksiyonlar
- Makale Koleksiyonu [5200]
- Makale Koleksiyonu [5745]
- Öksüz Yayınlar Koleksiyonu - WoS [6162]